Arcutis Biotherapeutics Inc (ARQT)
9.43
+0.17
(+1.84%)
USD |
NASDAQ |
Nov 18, 16:00
9.53
+0.10
(+1.06%)
Pre-Market: 08:17
Arcutis Biotherapeutics Gross Profit Margin (Quarterly): 87.70% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 87.70% |
| June 30, 2024 | 88.77% |
| March 31, 2024 | 93.43% |
| December 31, 2023 | 83.39% |
| September 30, 2023 | 96.90% |
| Date | Value |
|---|---|
| June 30, 2023 | 85.05% |
| March 31, 2023 | 71.84% |
| December 31, 2022 | 83.62% |
| September 30, 2022 | 62.90% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
62.90%
Minimum
Sep 2022
96.90%
Maximum
Sep 2023
83.73%
Average
85.05%
Median
Jun 2023
Gross Profit Margin (Quarterly) Benchmarks
| Mirum Pharmaceuticals Inc | 76.98% |
| Biogen Inc | 74.10% |
| Vertex Pharmaceuticals Inc | 85.84% |
| NovaBay Pharmaceuticals Inc | 65.26% |
| Palatin Technologies Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -139.0% |
| Return on Assets | -49.01% |
| Return on Invested Capital | -56.93% |
| Profit Margin (Quarterly) | -92.81% |
| Operating Margin (Quarterly) | -87.29% |
| Return on Net Operating Assets | -281.8% |